Left ventricular hypertrophy and sudden cardiac death-Reference-Cited by-同舟云学术

Left ventricular hypertrophy and sudden cardiac death

Published:2021-06-28 Issue: Volume: Page:
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Giamouzis Grigorios,Dimos Apostolos,Xanthopoulos Andrew,Skoularigis John,Triposkiadis Filippos^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10741-021-10134-5.pdf

Reference99 articles.

1. World Health Organization (1985) Sudden cardiac death : report of a WHO scientific group [meeting held in Geneva from 24 to 27 October 1984]. World Health Organization, Geneva

2. Al-Khatib SM et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138(13):e210–e271

3. Kober L et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230

4. Basso C et al (2017) Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology. Virchows Arch 471(6):691–705

5. Stecker EC et al (2006) Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 47(6):1161–1166

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review;American Heart Journal Plus: Cardiology Research and Practice;2024-08

3. Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial;BMJ Open;2024-08

4. Inhibition of Cholesteryl Ester Transfer Protein Contributes to the Protection of Ginsenoside Re Against Isoproterenol-Induced Cardiac Hypertrophy;Cureus;2024-05-09

5. Effect of Body Composition on Graft Function and Cardiovascular Outcomes in Normotensive Renal Transplant Recipients;Experimental and Clinical Transplantation;2024-02